You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Risk of hospitalisation doubles with Delta versus Alpha variant: Study

Vaccines from Pfizer Inc. and AstraZeneca Plc protect against delta, researchers said Monday

Coronavirus Vaccine | Pfizer | AstraZeneca

Katharine Gemmell | Bloomberg 

Photo: Bloomberg
Photo: Bloomberg

People infected with Covid-19’s delta variant, first detected in India, are more than twice as likely to end up in the hospital than with the alpha variant identified in the U.K. last year.

Vaccines from Inc. and Plc protect against delta, researchers said Monday. They found the shot made by and partner BioNTech SE offered better protection in a large study from Scotland.

The findings, presented in a research letter published in The Lancet, come as U.K. officials wrestle with whether to delay a lift in pandemic restrictions as the delta variant spreads.

ALSO READ: Delta variant 60% more transmissible, reduces vaccine effect: UK experts

“We need to encourage everyone to come forward and take up their offer of vaccination to ensure that they’ve had both of their doses,” Jim McMenamin, the Covid-19 incident director at Public Health Scotland, said at a media briefing.

Researchers from the Universities of Edinburgh and Strathclyde, as well as Public Health Scotland, found that the vaccine offered 92% protection against the alpha variant and 79% against the delta one 14 days after the second dose. That compared with 73% and 60% protection for the Astra vaccine. The authors warned that the vaccine comparison should be interpreted with caution due to the observational nature of the data.

The study covered a demographic distribution of cases in Scotland from April 1 to June 6. Researchers said a more complete analysis from these results would be made once it was combined with similar studies from the U.K. and elsewhere.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, June 14 2021. 21:07 IST